Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study

SIMPLE SUMMARY: Radium-223 prolongs overall survival in metastatic castration-resistant prostate cancer patients with bone metastases. However, prognosis after Radium-223 administration varies among patients. One possible reason for this heterogeneity could rely on the suboptimal selection of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauckneht, Matteo, Rebuzzi, Sara Elena, Ponzano, Marta, Borea, Roberto, Signori, Alessio, Frantellizzi, Viviana, Lodi Rizzini, Elisa, Mascia, Manlio, Lavelli, Valentina, Miceli, Alberto, De Feo, Maria Silvia, Pisani, Antonio Rosario, Nuvoli, Susanna, Tripoli, Vincenzo, Morganti, Alessio Giuseppe, Mammucci, Paolo, Caponnetto, Salvatore, Mantica, Guglielmo, Di Nicola, Angelo Domenico, Villano, Carlo, Cindolo, Luca, Morbelli, Silvia, Sambuceti, Gianmario, Fanti, Stefano, Costa, Renato Patrizio, Spanu, Angela, Rubini, Giuseppe, Monari, Fabio, De Vincentis, Giuseppe, Fornarini, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996965/
https://www.ncbi.nlm.nih.gov/pubmed/35406515
http://dx.doi.org/10.3390/cancers14071744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996965/
https://www.ncbi.nlm.nih.gov/pubmed/35406515
http://dx.doi.org/10.3390/cancers14071744

Ejemplares similares